The prognostic value for ADAM17 in pan-cancer was investigated by Kaplan-Meier analysis and found that the high expression of ADAM17 significantly decreased patients’ overall survival (OS) in four types of cancers, i.e., adrenocortical carcinoma (ACC), breast invasive carcinoma (BLCA), mesothelioma (MESO), and liver hepatocellular carcinoma (LIHC) (Figures 4I–L); whereas low expression of ADAM17 significantly decreased patient OS only in kidney renal clear cell carcinoma (KIRC) (Figure 4M). Here, ADAM17 is linked to invasive breast carcinoma.